三级淋巴结构在肺癌诊断和治疗中的应用现状和未来前景

Current status and future prospects for the use of tertiary lymphatic structures in the diagnosis and treatment of lung cancer

肺癌是全球发病率和病死率最高的恶性肿瘤之一,预后较差。薄层CT的普及,越来越多的早期肺癌被发现。近年来,胸腔镜技术、机器人手术技术不断革新,化疗、靶向治疗、免疫治疗等多种辅助治疗手段快速进展,为肺癌患者提供了多种治疗选择。但是肺癌患者的预后并没有得到明显改善,这一方面与肺癌患者总体预后较差有关,另一方面,也亟需寻找患者预后的有效预测标志物,精准筛选患者,进行针对性治疗,以期改善患者预后。本文就三级淋巴结构(tertiary lymphoid structures,TLSs)在肺癌中的应用进展作一综述,探讨TLSs在肺癌中的预后预测价值以及作为辅助治疗的生物标志物的可行性。

Lung cancer is one of the malignant tumors with the highest incidence and mortality rate worldwide and has a poor prognosis.With the popularization of thin layer CT,more and more early lung cancers are being detected.In recent years,thoracoscopic technology and robotic surgery technology have been innovated,and multiple adjuvant therapies such as chemotherapy,targeted therapy and immunotherapy have progressed rapidly,providing lung cancer patients with multiple treatment options.However,the prognosis of lung cancer patients has not been significantly improved,which is related to the overall poor prognosis of lung cancer patients on the one hand,and the urgent need to find effective predictive markers for patients'prognosis,to accurately screen patients,and to carry out targeted treatment in order to improve patients'prognosis on the other hand.In this paper,we review the progress of tertiary lymphoid structures(TLSs)in lung cancer and discuss the prognostic predictive value of TLSs in lung cancer and their feasibility as biomarkers for adjuvant therapy.